, The Lancet, vol.392, issue.18, pp.31644-31645, 2018.
Directly Observed Therapy (DOT) Definition [WWW Document, 2018. ,
,
, SIRTURO® (bedaquiline) Development and Launch
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis, Science, vol.307, pp.223-227, 2005. ,
Discounting in Economic Evaluations, Pharmacoeconomics, vol.36, pp.745-758, 2018. ,
, Tubeculose Actualites, 2018.
Procurement update: StopTB Partnership-Global Drug Dacility (GDF), 2018. ,
The Markov process in medical prognosis, Med Decis Making, vol.3, pp.419-458, 1983. ,
Nutritional Status of Adult Patients with Pulmonary Tuberculosis in Rural Central India and Its Association with Mortality, PLoS One, vol.8, 2013. ,
, Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR-and XDR-TB: a multicentre study, vol.49, 2017.
Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy, Journal of Market Access & Health Policy, vol.5, p.1283105, 2017. ,
The NIX-TB trial of pretomanid, 2017. ,
, Country Updates, 2018.
Big pharma's market access mission, 2018. ,
,
Multidrug-resistant tuberculosis and culture conversion with bedaquiline, N. Engl. J. Med, vol.371, pp.723-732, 2014. ,
Methods for the Economics Evaluation of Health Care Programmes, 2015. ,
Études coût-efficacité: idées fausses et éléments de méthode. Archives of Cardiovascular Diseases Supplements, Rapport coût-effi cacité des traitements médicamenteux et interventionnels dans la fibrillation atriale 8, EndTB Interim Analysis. Global Snapshot, issue.16, pp.30329-30338, 2016. ,
, , 2018.
Long-term outcome and safety of prolonged bedaquiline treatment for multidrugresistant tuberculosis, Eur. Respir. J, vol.49, 2017. ,
DOI : 10.1183/13993003.01799-2016
URL : https://hal.archives-ouvertes.fr/hal-01489714
India : International Health Care System Profiles [WWW Document]. The Common wealth fund, vol.18, 2016. ,
The Disability-Adjusted Life Year (DALY) Definition, Measurement and Potential Use, 1996. ,
, , vol.18
Factors that associated with TB patient admission rate and TB inpatient service cost: a cross-sectional study in China, Infect Dis Poverty, vol.5, 2016. ,
DOI : 10.1186/s40249-016-0097-x
URL : https://idpjournal.biomedcentral.com/track/pdf/10.1186/s40249-016-0097-x
Bedaquiline-versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis, Expert Review of Pharmacoeconomics & Outcomes Research, vol.18, pp.677-689, 2018. ,
DOI : 10.1080/14737167.2018.1507821
URL : https://www.tandfonline.com/doi/pdf/10.1080/14737167.2018.1507821?needAccess=true
, , 2016.
SIRTURO® (bedaquiline)| Mechanism of Action [WWW Document, SIRTURO® Official website, 2018. ,
Janssen joins partnership in China to provide access to SIRTURO® (bedaquiline) for the treatment of multidrug-resistant tuberculosis (MDR-TB) | Xian Janssen Pharmaceutical Ltd, 2018. ,
Janssen remporte le Prix Galien International 2016 pour la bédaquiline, 2016. ,
,
Would pan-tuberculosis treatment regimens be cost-effective?, The Lancet Respiratory Medicine, vol.6, pp.30197-30205, 2018. ,
DOI : 10.1016/s2213-2600(18)30197-8
Health Economics: An introduction to Economic Evaluation, The Office of Health Economics (OHE), 2002. ,
Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis, J. Biol. Chem, vol.283, pp.25273-25280, 2008. ,
Pharmaceutical market access in emerging markets: concepts, components, and future, J Mark Access Health Policy, vol.2, 2014. ,
DOI : 10.3402/jmahp.v2.25302
URL : https://doi.org/10.3402/jmahp.v2.25302
L'évaluation médico-économique-Concepts et méthodes, Editions Le Grand Metier, 2018. ,
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis, L'Institut Pasteur veut ressusciter le BCG avec des souches centenaires. 03/04/2018. Lee, vol.367, pp.1508-1518, 2012. ,
The use of delamanid in the treatment of multidrug-resistant tuberculosis in children and adolescents: interim policy guidance, 2016. ,
Understanding latent tuberculosis: a moving target, J. Immunol, vol.185, pp.15-22, 2010. ,
DOI : 10.4049/jimmunol.0903856
URL : http://www.jimmunol.org/content/jimmunol/185/1/15.full.pdf
, Live China population, 2018.
, , vol.18
Patient medical costs for tuberculosis treatment and impact on adherence in China: a systematic review, BMC Public Health, vol.11, 2011. ,
Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries, BMC Health Services Research, vol.17, 2017. ,
, South Africa Becomes First Country to Include New, More Effective DRTB Drug in Standard Treatment [WWW Document]. Doctors Without Borders-USA, 2018.
, Ministry of Health & Family Welfare, National Health Policy, 2014.
Catastrophic costs of treating drug resistant TB patients in a tertiary care hospital in India, Indian Journal of Tuberculosis, 2018. ,
Household Catastrophic Health Expenditure Due to Tuberculosis : Analysis from Particularly Vulnerable Tribal Group, 2015. ,
Financial Implications in Management of Multidrug Resistant Tuberculosis in India, International Journal of Science and Research (IJSR), vol.6, pp.535-539, 2017. ,
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis, Eur. Respir. J, vol.49, 2017. ,
Long-term bedaquiline-related treatment outcomes in patients with extensively drugresistant tuberculosis from South Africa, European Respiratory Journal, vol.51, 2018. ,
, OMS, 2018.
OMS lance un appel à agir d'urgence pour mettre fin à la tuberculose ,
, OMS, 2018.
, Rapid Communication: Key changes to treatment of multidrug-and rifampicin-resistant tuberculosis (MDR/RR-TB) 9, OMS, 2018.
, OMS, 2017.
, Seuils de rentabilité: avantages et inconvénients, OMS, 2016.
, Cost-effectiveness thresholds: pros and cons, OMS, 2016.
,
Les différents types de résistance aux médicaments antituberculeux ,
Health Profile of India [WWW Document ,
Health profile of China [WWW Document ,
World Health Organization: Tuberculosis in China a Disease of Poverty ,
, WHO treatment guidelines for drug-resistant tuberculosis: 2016 update, OMS, 2016.
How Pharmaceutical systems are organized in Asia and the Pacific, 2018. ,
, Pour le ministre indien de la santé, « l'heure est venue d'en finir avec la tuberculose, OPINIONS, 2018.
Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study, Journal of Antimicrobial Chemotherapy, vol.69, pp.3103-3107, 2014. ,
Disparity in reimbursement for tuberculosis care among different health insurance schemes: evidence from three counties in central China, Infect Dis Poverty, vol.5, 2016. ,
Costeffectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea, Clinical Therapeutics, vol.38, pp.655-667, 2016. ,
Catastrophic costs of tuberculosis care: a mixed methods study from Puducherry, India. Glob Health Action, vol.11, 2018. ,
Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis, Eur. Respir. J, vol.47, pp.564-574, 2016. ,
Socio-economic impact of tuberculosis on patients and family in India, The International Journal of Tuberculosis and Lung Disease, issue.10, pp.869-77, 1999. ,
,
Central TB Division, Ministry of Health and Family Welfare, RNTCP, 2014. ,
Sirturo (Bedaquiline Tablets) [WWW Document, 2017. ,
Macroeconomics and health: investing in health for economic development ; report of the Commission on Macroeconomics and Health. OMS, Geneva. Sandesh Adhikari, 2017. DALY (Disability Adjusted Life Years), 2001. ,
Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study, The Lancet Respiratory Medicine, vol.6, issue.18, pp.30235-30237, 2018. ,
Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience, Int J Mycobacteriol, vol.5, issue.1, pp.62-63, 2016. ,
Global Drug Facility (GDF) [WWW Document, vol.18, 2018. ,
The Bedaquiline Donation Program [WWW Document, 2018. ,
Access to and affordability of healthcare for TB patients in China: issues and challenges, TB Facts | TB, tests, drugs, vol.5, 2016. ,
, Eligibility List, p.408030000000, 2018.
, South Africa announces lower price for TB drug bedaquiline [WWW Document]. The Union, 2018.
, Caractéristiques de Mycobacterium tuberculosis-Tuberculosis
Cost-effectiveness of introducing Bedaquiline in MDR-TB regimens-a exploratory analysis, 2013. ,
L'histoire de la tuberculose et de ses traitements, 1994. ,
The Global Fund in China: Multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership, PLOS ONE, vol.12, 2017. ,
New drug to be provided free to Chinese TB patients, 2018. ,
What is an Antibiotic?, Antibiotics: Current Innovations and Future Trends, 2015. ,
The true meaning of market access?, 2012. ,
, , vol.18
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany, European Respiratory Journal, vol.46, pp.1826-1829, 2015. ,
Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK, PLOS ONE, vol.10, 2015. ,
, Drug-Resistant Infections: A Threat to Our Economic Future, 2016.
Household catastrophic health expenditure: a multicountry analysis, The Lancet, vol.362, pp.13861-13866, 2003. ,
Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study, Clin. Infect. Dis, 2018. ,
Factors that determine catastrophic expenditure for tuberculosis care: a patient survey in China, Infectious Diseases of Poverty, vol.5, 2016. ,
, , 2014.